BACKGROUND: The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs. METHODS: In an open-label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz group), lopinavir-ritonavir plus two NRTIs (lopinavir-ritonavir group), and lopinavir-ritonavir plus efavirenz (NRTI-sparing group). We randomly assigned 757 patients with a median CD4 count of 191 cells per cubic millimeter and a median HIV-1 RNA level of 4.8 log10 copies per milliliter to the three groups. RESULTS: At a median follow-up of 112 weeks, the time to virologic failure was longer in the efavirenz group than in the lopinavir-ritonavir group (P=0.006) but was not significantly different in the NRTI-sparing group from the time in either of the other two groups. At week 96, the proportion of patients with fewer than 50 copies of plasma HIV-1 RNA per milliliter was 89% in the efavirenz group, 77% in the lopinavir-ritonavir group, and 83% in the NRTI-sparing group (P=0.003 for the comparison between the efavirenz group and the lopinavir-ritonavir group). The groups did not differ significantly in the time to discontinuation because of toxic effects. At virologic failure, antiretroviral resistance mutations were more frequent in the NRTI-sparing group than in the other two groups. CONCLUSIONS:Virologic failure was less likely in the efavirenz group than in the lopinavir-ritonavir group. The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz regimen but was more likely to be associated with drug resistance. (ClinicalTrials.gov number, NCT00050895 [ClinicalTrials.gov].). Copyright 2008 Massachusetts Medical Society.
RCT Entities:
BACKGROUND: The use of either efavirenz or lopinavir-ritonavir plus two nucleoside reverse-transcriptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection, but which of the two regimens has greater efficacy is not known. The alternative regimen of lopinavir-ritonavir plus efavirenz may prevent toxic effects associated with NRTIs. METHODS: In an open-label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz group), lopinavir-ritonavir plus two NRTIs (lopinavir-ritonavir group), and lopinavir-ritonavir plus efavirenz (NRTI-sparing group). We randomly assigned 757 patients with a median CD4 count of 191 cells per cubic millimeter and a median HIV-1 RNA level of 4.8 log10 copies per milliliter to the three groups. RESULTS: At a median follow-up of 112 weeks, the time to virologic failure was longer in the efavirenz group than in the lopinavir-ritonavir group (P=0.006) but was not significantly different in the NRTI-sparing group from the time in either of the other two groups. At week 96, the proportion of patients with fewer than 50 copies of plasma HIV-1 RNA per milliliter was 89% in the efavirenz group, 77% in the lopinavir-ritonavir group, and 83% in the NRTI-sparing group (P=0.003 for the comparison between the efavirenz group and the lopinavir-ritonavir group). The groups did not differ significantly in the time to discontinuation because of toxic effects. At virologic failure, antiretroviral resistance mutations were more frequent in the NRTI-sparing group than in the other two groups. CONCLUSIONS:Virologic failure was less likely in the efavirenz group than in the lopinavir-ritonavir group. The virologic efficacy of the NRTI-sparing regimen was similar to that of the efavirenz regimen but was more likely to be associated with drug resistance. (ClinicalTrials.gov number, NCT00050895 [ClinicalTrials.gov].). Copyright 2008 Massachusetts Medical Society.
Authors: Dale J Kempf; Martin S King; Barry Bernstein; Paul Cernohous; Eric Bauer; Jennifer Moseley; Kai Gu; Ann Hsu; Scott Brun; Eugene Sun Journal: J Infect Dis Date: 2003-12-31 Impact factor: 5.226
Authors: R L Murphy; S Brun; C Hicks; J J Eron; R Gulick; M King; A C White; C Benson; M Thompson; H A Kessler; S Hammer; R Bertz; A Hsu; A Japour; E Sun Journal: AIDS Date: 2001-01-05 Impact factor: 4.177
Authors: S Staszewski; J Morales-Ramirez; K T Tashima; A Rachlis; D Skiest; J Stanford; R Stryker; P Johnson; D F Labriola; D Farina; D J Manion; N M Ruiz Journal: N Engl J Med Date: 1999-12-16 Impact factor: 91.245
Authors: Charles Hicks; Martin S King; Roy M Gulick; A Clinton White; Joseph J Eron; Harold A Kessler; Constance Benson; Kathryn R King; Robert L Murphy; Scott C Brun Journal: AIDS Date: 2004-03-26 Impact factor: 4.177
Authors: S R Vlahakis; G D Bren; A Algeciras-Schimnich; S A Trushin; D J Schnepple; A D Badley Journal: Clin Pharmacol Ther Date: 2007-03-14 Impact factor: 6.875
Authors: Sharon Walmsley; Barry Bernstein; Martin King; José Arribas; Gildon Beall; Peter Ruane; Margaret Johnson; David Johnson; Richard Lalonde; Anthony Japour; Scott Brun; Eugene Sun Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: Regina B Osih; Patrick Taffé; Martin Rickenbach; Angèle Gayet-Ageron; Luigia Elzi; Christoph Fux; Milos Opravil; Enos Bernasconi; Patrick Schmid; Huldrych F Günthard; Matthias Cavassini Journal: AIDS Res Hum Retroviruses Date: 2010-10-07 Impact factor: 2.205
Authors: Judith N Dlamini; Zonghui Hu; Harsha Somaroo; Helene C Highbarger; Dean A Follmann; Robin L Dewar; Alice K Pau Journal: Pharmacotherapy Date: 2011-02 Impact factor: 4.705
Authors: Nina Mani; Jeffrey Murray; Roy M Gulick; Filip Josephson; Veronica Miller; Peter Miele; Jur Strobos; Kimberly Struble Journal: AIDS Date: 2012-05-15 Impact factor: 4.177
Authors: C William Wester; Ori M Stitelman; Victor deGruttola; Hermann Bussmann; Richard G Marlink; Mark J van der Laan Journal: AIDS Res Hum Retroviruses Date: 2012-03-23 Impact factor: 2.205
Authors: Heather J Ribaudo; Kimberly Y Smith; Gregory K Robbins; Charles Flexner; Richard Haubrich; Yun Chen; Margaret A Fischl; Bruce R Schackman; Sharon A Riddler; Roy M Gulick Journal: Clin Infect Dis Date: 2013-09-17 Impact factor: 9.079